Rohith Jesudas

Rohith Jesudas

Auto-generated profile, based on publicly available information

Rohith Jesudas

Bleeding and Clotting Disorders Institute, Peoria, Illinois

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2019 in Haemophilia
Verified
Journal Article
Closed access
PDF file
RJRohith Jesudas
Rohith Jesudas
ACAteefa Chaudhury
Ateefa Chaudhury
CLChristina M. Laukaitis
Christina M. Laukaitis

1 April 2019 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
EAEman T. Al-Antary
Eman T. Al-Antary
RJRohith Jesudas
Rohith Jesudas
AGAmy George
Amy George
JPJanet Poulik
Janet Poulik
SSSüreyya Savaşan
Süreyya Savaşan
Syncytial variant of nodular sclerosis (SV-NS) classical Hodgkin lymphoma (cHL) with its histologic features and clinical presentation is uncommon in adults and extremely rare in children. Here, we report a female teenager presenting with long-standing B symptoms, prominent soft tissue and bone involvement mimicking sarcoma and significant nodal disease who is diagnosed with advanced SV-NS cHL. Rare Reed-Sternberg-like cells displaying neutrophil and erythrocyte emperipolesis were seen on bone marrow aspiration slides. Despite initial complete response to chemotherapy and radiotherapy, the patient experienced early relapse suggestive of high-risk biology. This variant may constitute a unique entity.


23 June 2021 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Open access
NKNicole Elizabeth Kendel
Nicole Elizabeth Kendel
SOSarah H. O’brien
Sarah H. O’brien
CLChristina M. Laukaitis
Christina M. Laukaitis
MKManjusha Kumar
Manjusha Kumar
HLHoward P. Levy
Howard P. Levy
RJRohith Jesudas
Rohith Jesudas
The association between bleeding and joint hypermobility may not be as diagnostically obvious in patients with milder connective tissue disorders. We surveyed members of the Hemostasis and Thrombosis Research Society regarding their knowledge, evaluation, and management practices in patients with generalized hypermobility spectrum disorder/hypermobile Ehlers–Danlos syndrome (hEDS) and bleeding symptoms. The objectives of this study were to (1) evaluate hematologists’ diagnosis and management practices for patients with bleeding symptoms and generalized hypermobility spectrum disorder/hEDS and (2) determine future education and research priorities regarding bleeding symptoms within this population. Evaluate hematologists’ diagnosis and management practices for patients with bleeding symptoms and generalized hypermobility spectrum disorder/hEDS. Determine future education and research priorities regarding bleeding symptoms within this population. A web-based survey was sent to Hemostasis and Thrombosis Research Society physician members. Physician demographics, preferred evaluation for hEDS, management of bleeding episodes, and referral patterns were collected and descriptive statistics were performed. Only two-thirds of respondents reported evaluating for hypermobility, despite all respondents being aware of the association with bleeding. There were significant variations in referral patterns for genetic counseling, diagnostic evaluation, and management of nonhematologic symptoms. There were also significant variations in reported medical homes for this patient population. Research prioritization included understanding the evolution of bleeding symptoms with age in this population as well as the development of functional tests to identify the molecular mechanism of bleeding and the development of novel hemostatic agents for this population. Results from 33 respondents show differing physician practices regarding the evaluation and management of bleeding in hypermobile patients. Many physicians suggested further research priorities to include studying the natural history of the disease and development of functional diagnostic testing as well as targeted therapeutic options in this patient population.

28 February 2019 in Haemophilia
Verified
Journal Article
Closed access
PDF file
SWShanna White
Shanna White
RJRohith Jesudas
Rohith Jesudas
TBTerrance M. Brady
Terrance M. Brady
MTMichael D. Tarantino
Michael D. Tarantino

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KSKate Shapiro
Kate Shapiro
JWJoshua Wolf
Joshua Wolf
RJRohith Jesudas
Rohith Jesudas
JWJeffrey C Winer
Jeffrey C Winer
SASandra Arnold
Sandra Arnold
Children with sickle cell disease (SCD) commonly develop microvascular infarcts of bone known as vaso-occlusive crisis (VOC) and are also at high risk of osteomyelitis (OM). VOC and OM can be challenging to distinguish due to overlapping clinical features. VOC might predispose to OM, or an initial misdiagnosis of OM as VOC might lead to delayed diagnosis of OM. This study aimed to test whether VOC was associated with subsequent development of OM in children with SCD. A retrospective Pediatric Health Information System (PHIS) database study (2010-2021) was performed. ICD-code data related to common diagnoses in pediatric patients with SCD were extracted. The rate of VOC within 30 and 180 days preceding episodes of OM was compared to the rate preceding acute chest syndrome (ACS), another common diagnosis in children with SCD but unlikely to be anatomically related to OM. Odds ratios (OR) were used to evaluate the association between these diagnoses. Of 22,818 PHIS participants with SCD, 13,699; 450; and 7,327 had ≥ 1 episode of VOC, OM and ACS, respectively. The distribution of OM diagnoses was similar across pre-specified age groups (0-4, 5-12, and 13-18 years). The odds ratio of VOC preceding a diagnosis of OM vs. ACS was 2.15 within 30 days (95% CI: 1.82-2.54; p= 3.68 x 10-18), and within 180 days was 1.39 (95% CI: 1.20-1.62; p=2.04 x 10-5). VOC was significantly more common in the days preceding a diagnosis of OM than of ACS. The strength of association was stronger within 30 days prior to OM than 180 days. These results suggest possible misdiagnosis of OM since VOC might delay OM diagnosis in some cases, that recurrent VOC might be misdiagnosed as OM, or that VOC can directly contribute to risk of OM in some cases. Limitations of this study include possible incomplete adjustment for unmeasured variables which could confound the analysis. More research is needed to confirm and evaluate the mechanism behind this association. Understanding the relationship could lead to improved screening and treatment of both VOC and OM. Joshua Wolf, MBBS, PhD, Karius Inc.: Grant/Research Support|Merck Inc.: Participation in industry-sponsored research Sandra Arnold, MD, Contrafect: Grant/Research Support|Enanta: Grant/Research Support|Moderna: Grant/Research Support|Pfizer: Grant/Research Support